Biogen Inc. Common Stock
$215.50
-$3.55 (-1.62%)
$215.26Day Range$220.17
Key Statistics
Market Cap
$31.84B
Shares Outstanding
147.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 17, 1991
Round Lot
100
Locale
US
Trading Data
Day Open
$219.05
Day High
$220.17
Day Low
$215.26
Volume
2.64M
VWAP
$216.08
Prev Close
$219.05
Transactions
--
Acc. Volume
--
About Biogen Inc. Common Stock
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 28367,500 employees225 BINNEY STREET, CAMBRIDGE, MA, 02142(617) 679-2000IPO Sep 17, 1991US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000875045
- Composite FIGI
- BBG000C17X76
- Share Class FIGI
- BBG001S67826
- Ticker Root
- BIIB
- SIC Code
- 2836
About Biogen Inc. Common Stock (BIIB) Stock
Biogen Inc. Common Stock (BIIB) closed the 2026-09-18 session at $215.50, down 1.62% versus the previous close (-3.55). The stock opened at $219.05 and traded between $215.26 and $220.17 during that session. Session trading volume was 2.6M shares. The volume-weighted average price (VWAP) is $216.08.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Biogen Inc. Common Stock has a market capitalization of $31.84 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. BIIB is listed on the XNAS exchange. The company employs approximately 7,500 people. Biogen Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 1991-09-17.
On this page you can find market BIIB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.